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a b s t r a c t
Introduction: Cancer pathogenesis and resulting treatment may lead to bone loss and poor skeletal health in survivorship. The purpose of this investigation was to evaluate the inﬂuence of 26 weeks of combined aerobic and resistance-training (CART) exercise on bone mineral density (BMD) in a multi-racial sample of female cancer survivors.
Methods: Twenty-six female cancer survivors volunteered to undergo CART for 1 h/day, 3 days/week, for 26 weeks.
The Improving Physical Activity After Cancer Treatment (IMPAACT) Program involves supervised group exercise
sessions including 20 min of cardiorespiratory training, 25 min of circuit-style resistance-training, and 15 min of abdominal exercises and stretching. BMD at the spine, hip, and whole body was assessed using dual-energy X-ray absorptiometry (DXA) before and after the intervention. Serum markers of bone metabolism (procollagen-type I Nterminal propeptide, P1NP, and C-terminal telopeptides, CTX) were measured at baseline, 13 weeks, and at study
completion.
Results: Eighteen participants, with the average age of 63.0 ± 10.3 years, completed the program. Mean duration
since completion of cancer treatment was 6.2 ± 10.6 years. Paired t-tests revealed signiﬁcant improvements in
BMD of the spine (0.971 ± 0.218 g/cm2 vs. 0.995 ± 0.218 g/cm2, p = 0.012), hip (0.860 ± 0.184 g/cm2 vs.
0.875 ± 0.191 g/cm2, p = 0.048), and whole body (1.002 ± 0.153 g/cm2 vs. 1.022 ± 0.159 g/cm2, p = 0.002).
P1NP declined 22% at 13 weeks and 28% at 26 weeks in comparison to baseline (p b 0.01) while CTX showed a
non-signiﬁcant decrease of 8% and 18% respectively.
Conclusions: We report signiﬁcant improvements in BMD at the spine, hip, and whole body for female cancer survivors who completed 26 weeks of CART. This investigation demonstrates the possible effectiveness of CART at improving bone health and reducing risk of osteoporosis for women who have completed cancer treatment. The
IMPAACT Program appears to be a safe and feasible way for women to improve health after cancer treatment.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Improvements in cancer treatment and detection, as well as growth
of the population, have led to increased survival rates among those diagnosed with cancer. As of 2014, there was an estimated 14.5 million cancer survivors in the United States, 64% who are 5-year survivors, while
15% are 20-year survivors [1]. Cancer survivors are living longer but

Abbreviations: BMD, bone mineral density; BTM, bone turnover marker; CART,
combined aerobic and resistance training; CTX, C-terminal telopeptides; DXA, dualenergy X-ray absorptiometry; FFQ, food frequency questionnaire; IMPAACT, improving
physical activity after cancer treatment; P1NP, procollagen-type I N-terminal
propeptides; NTX, N-telopeptide cross-linked collagen type I.
⁎ Corresponding author at: Department of Health and Human Sciences, 1 LMU Drive,
MS 8888, Loyola Marymount University, Los Angeles, CA 90045, USA.
E-mail address: Hawley.almstedt@lmu.edu (H.C. Almstedt).

experience greater comorbidity than age-matched peers who never
had cancer. Survivors demonstrate comorbidities such as higher rates
of obesity, type 2 diabetes, cardiovascular disease, and osteoporosis
[2–4]. Osteoporosis is a chronic disease of low bone mass, characterized
by skeletal fragility and increased risk for fracture. Women experience a
greater burden of this disease accounting for 80% of people with
osteoporosis.
Previous research reports that 12 months of treatment for a gynecological cancer can cause 6–10% reduction in bone mineral density
(BMD) due to elevated resorption during treatment [5]. Elevated resorption and its associated loss in BMD increases risk for fracture. In
fact, women with a history of breast cancer experience signiﬁcantly
more skeletal fractures than women who never had breast cancer [6].
Bone loss during cancer treatment appears to be in addition to losses experienced with cessation of ovarian function. Survivors of gynecological
cancers, who were diagnosed before menopause and underwent
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ovarectomy, demonstrate 7–9% lower BMD than similarly aged women
who underwent an ovariectomy for non-cancerous reasons [7].
Cancer and its treatment may lead to poor skeletal health via several
mechanisms. Secretions from tumors themselves can speed up osteoclast activity, increasing bone resorption [8]. This interference with normal bone signaling pathways is observed in both male and female
cancer survivors and is frequently quantiﬁed as an elevated serum
level of P1NP [9,10]. Subsequently, P1NP is valuable as both an indicator
of risk for tumor invasion of the bone and as a traditional bone turnover
marker (BTM) for measuring skeletal response to pharmacologic and
non-pharmacologic interventions for poor BMD. For cancer patients, assessment of both the possibility for metastasis and normal/abnormal
BMD are essential to promoting skeletal health during survivorship. In
addition to the aforementioned burden of tumor interference, female
cancer patients frequently encounter additional skeletal health challenge due to the surgery or chemotherapy necessary for cancer treatment which may also induce ovarian dysfunction and lead to early
menopause and its associated bone loss [11]. Also, long-term use of
antihormonal medications, which are often part of the cancer therapy,
negatively impact bone health [6]. All of the mechanisms discussed
here will have systemic inﬂuence on bone health, however radiation
treatment can cause site-speciﬁc bone loss [12].
Multiple studies have demonstrated that weight-bearing exercise
can improve or help maintain BMD and lower risk for fracture in pre
and postmenopausal women [13,14]. Weight-bearing aerobic activities
and resistance training performed multiple times per week are recommended to help preserve bone health during adulthood [15]. In addition, some research supports use of whole body vibration as a training
method which may potentially be osteogenic [16,17]. Exercise is a
nonpharmacological, low-cost approach, with the potential to improve
or maintain bone health and additional likely beneﬁts to cardiovascular
ﬁtness, body weight management, balance, and risk for falling. Exercise
programming which combines aerobic and resistance training exercise
may simultaneously help to address multiple comorbidities of cancer
such as obesity, cardiovascular disease, type 2 diabetes, and osteoporosis. Little is known about the volume of exercise that is safe for cancer
survivors and that is effective at maintaining or improving bone health
[18]. With the recent increase in the number of cancer survivors and the
multiple ways cancer and its treatment may affect the skeleton, there is
a need to develop survivorship care plans which include exercise as a
means to sustain bone health in women and reduce comorbidities.
Therefore, the purpose of this investigation was to evaluate the inﬂuence of 26 weeks of combined aerobic and resistance-training (CART)
exercise on bone mineral density (BMD) in a convenience sample of female cancer survivors.
2. Materials and methods
2.1. Ethical approval
The IMPAACT Study was approved by the Human Subject's Institutional Review Board at Loyola Marymount University. All research participants provided written informed consent. Procedures performed in
this study involving human participants were in accordance with the
ethical standards of the Loyola Marymount University Institutional Review Board which uses the 1964 Helsinki declaration and its later
amendments as ethical standards.
2.2. Participants and anthropometrics
The Improving Physical Activity After Cancer Treatment (IMPAACT)
Study recruited 26 female cancer survivors from the Los Angeles area to
participate in the exercise intervention using convenience sampling and
physician referral. Eighteen of the volunteers completed the 26-week
intervention including testing at baseline and follow up. Volunteers
were excluded if currently receiving intravenous chemotherapy or
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outpatient radiation therapy. Primary care physicians and oncologists
were notiﬁed of their patient's participation. Weight and height were
assessed in minimal clothing, without shoes, where weight was measured on an electronic scale (Tanita BWB-927A Tokyo, Japan) and
height was assessed using a stadiometer (Seca Accu-Hite, Columbia,
MD, USA). Body mass index (BMI) was calculated by dividing weight
in kg by height in meters squared.
2.3. Assessments
Demographic characteristics and medical history were obtained at
baseline via self-administered questionnaires. The Aerobic Center Longitudinal Study Physical Activity Questionnaire was used to assess regular physical activity by calculating metabolic equivalents in hours per
week by using intensity of activity, age, body weight, and duration
[19]. The Block 2005 Food Frequency Questionnaire (FFQ) was used to
measure dietary intake over the previous year for nutrients important
for bone health, including calcium and vitamin D. This questionnaire
uses photos to help users more accurately estimate portion size and
has been validated to assess dietary intake over the previous 12 months
[20].
2.4. Bone health and body composition
Bone mineral density of the posterior-anterior spine, left hip, and
whole body were measured using dual energy X-ray absorptiometry
(DXA, Hologic Discovery A, Waltham, MA). One technician performed
and analyzed all scans. This technician demonstrates 1.0% test-retest reliability for BMD at the hip and spine. The whole body DXA scan allows
for analysis of lean mass and fat mass. Participants provided fasting
blood samples early in the morning at baseline, 13 weeks, and 26
weeks. Serum samples were processed and stored at − 20 °C within
2 h of collection and moved for long-term storage at − 80 °C, 24 h
later. Procollagen-type I N-terminal propeptide (P1NP, ng/mL) a measure of bone formation cleaved off in production of type I collagen was
assessed by enzyme-linked immunosorbent assay (ELISA) kits from
Cloud Clone Corp (Houston, TX). Serum levels of C-terminal
telopeptides (CTX, ng/mL) were measured as a marker of bone resorption via ELISA kits from Immuno Diagnostic Systems (Fountain Hills,
AZ). Bone turnover markers (BTMs) were assayed at the UCLA Bone
Histomorphometry Laboratory with coefﬁcients of variation (CV) as follows PINP inter-assay CV of b 12%, P1NP intra-assay CV of b10%, CTX
inter-assay CV of 2.5–10.9%, and CTX intra-assay CV of 1.8–3.0%.
2.5. Exercise program
The IMPAACT Study was a combined aerobic and resistance training
program which occurred 1 h per day, 3 days per week, for 26 weeks. The
supervised exercise intervention took place on the Loyola Marymount
University campus in Los Angeles, CA following the academic calendar;
beginning in August/September, taking a break for winter and spring
holidays, then concluding in April/May. Therefore, the 26-week exercise
program was actually spread over 32 weeks of the year. Prescribed in
accordance with Guidelines for Exercise for Cancer Survivors from the
American College of Sports Medicine (ACSM), each supervised exercise
session includes a) 20 min of cardiorespiratory training, b) 25 min of circuit-style resistance training, and c) 15 min of exercises for the core
musculature with dynamic and static stretching [21]. The IMPAACT
study intervention incorporated both aerobic and resistance training
components, in effort to meet the American College of Sports Medicine
Guidelines on Exercise for Cancer Survivors and to help to reduce the
multiple comorbidities exhibited by cancer survivors.
Cardiorespiratory training included walking although weather and
ﬁtness levels required the occasional inclusion of elliptical machines,
or stationary bicycles at a prescribed target hear rate training zone of
35–80% heart rate reserve. In accordance with baseline activity levels,
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physical ﬁtness, and medical history, prescribed cardiovascular intensity was determined using the Karvonen formula [exercise target heart
rate = (heart rate reserve) × % of target exercise intensity + heart
rate at rest)]. Heart rates from chest-strap monitors (RS800CX, Polar
Electro, Lake Success, NY) were obtained for each participant multiple
times during the cardiorespiratory training and ratings of perceived exertion (RPE) values were obtained at the end of the cardiorespiratory
portion and re-evaluated for progression every 2–3 weeks [22]. At the
start of the program participants were prescribed values of 35–50% of
heart rate reserve but were progressively increased over time based
on heart rate and RPE relationships.
The resistance training circuit included eight upper and lower body
resistance exercises provided through use of body weight, dumbbells,
elastic bands, varied body positions, and altered step height. Exercises
included upper body rows, squats, step-ups, push-ups, lunges, resisted
shoulder and hip abduction movements, and balance drills. Participants
were introduced to the 10-station resistance-training circuit over a twoweek period and by the third week performed each exercise for 45 s
followed by 20 s rest in a circuit fashion, achieving three sets of each exercise during the workout. Utilizing the circuit-style of resistance training, exact numbers of repetitions were not recorded, however coaching
and supervision would suggest movement speeds consistent with 12–
15 repetitions per set. Load and repetitions were guided by RPE and individual HR zone prescription. To ensure safety, participants aimed to
reach exertion of 7–8 (out of 10) on the RPE scale while maintaining
HR in close proximity to their prescribed HR zone. Participants selfmonitored both variables and were encouraged to modify exercise by
altering the number of repetitions or adjusting resistance in order to
comply with aforementioned recommendations. Whole body vibration
on a Vibraﬂex 550 platform (Novotec, Pforzheim, Germany) was included as two stations in each circuit. Whole body vibration commenced at
30 s and 20 Hz for the ﬁrst 4 weeks and advanced to 45 s and 25 Hz with
participants performing straightforward movements such as toe/heel
raises and partial squats simultaneously during vibration exposure.
The program was carefully supervised by research assistants to ensure
exercise adherence and training increased intensity every two to three
weeks.
2.6. Statistical analysis
Paired t-tests, performed with SPSS version 22 (IBM Corporation,
Armonk, NY, USA), were used to evaluate signiﬁcant changes in BMD
from baseline to follow up. Repeated measures analysis of variance
(ANOVA) was used to evaluate change in P1NP and CTX over time.
3. Results
Twenty-six female cancer survivors volunteered to participate in the
exercise intervention, while 18 completed 26 weeks of the exercise intervention and the follow-up assessments. Three volunteers withdrew
from the program due to cancer recurrence and return to treatment.
Three participants were unable to complete the full 26 week IMPAACT
program because they underwent post-treatment reconstructive surgeries that required downtime from exercise. Two volunteers dropped
from the study due to scheduling conﬂicts with work and personal matters. Baseline characteristics for the 18 participants who completed
baseline and follow-up testing are presented in Table 1.
Twelve participants identiﬁed their race/ethnicity as White, ﬁve
identiﬁed as Black/African American, and one Hispanic/Latina. Most volunteers were treated for breast cancer (n = 12, 67%), while other cancer
types included colorectal (n = 3, 17%), Hodgkin's lymphoma (n = 1,
5%), thyroid (n = 1, 5%), and both breast and colon cancer (n = 1,
5%). Table 1 displays the percent of participants who underwent surgery, chemotherapy, and/or radiation as a treatment. All participants
experienced one of these treatments and many experienced two or
more. Most of the participants (89%) had undergone menopause before

Table 1
Demographic characteristics at baseline.
Characteristic

Mean

Standard deviation

Age (years)
BMI (kg/m2)
Calcium intake (mg/d)
Vitamin D intake (IU/d)
Physical activity (MET-h/wk)
Spine T-score
Total hip T-score
Time since treatment (years)
Chemotherapy (% yes)
Radiation therapy (% yes)
Surgical treatment (% yes)

63.0
30.0
1179
621
19.2
−1.01
−0.86
6.2
44%
72%
83%

10.3
7.0
600
268
12.0
1.82
1.26
10.6

BMI is body mass index.
MET is metabolic equivalents.

the study began, however two volunteers were premenopausal. The average time since menopause was 17.1 ± 9.9 years. At baseline, four participants were taking a medication known to alter bone health; 1 was
taking a bisphosphonate, 1 was taking prednisone, 2 participants were
taking an aromatase inhibitor one of which was also taking a RANK ligand inhibitor (denosumab). During the study, two additional participants initiated oral bisphosphonate medication use weekly while one
volunteer ceased the aromatase inhibitor. The average recorded attendance for the exercise sessions was 63% ± 17.3. No injuries or adverse
effects due to the CART exercise sessions were reported by participants.
The average body mass index (BMI, kg/m2) is presented in Table 1.
Most participants were obese (n = 9, 50%) or overweight (n = 6,
33%), while two were of normal body weight for their height, and one
was underweight (BMI ≤ 18.5). Data presented in Table 1 for calcium
and vitamin D intake includes dietary and supplemental sources of
these nutrients. The average calcium intake appeared to be adequate
for most adults; 1000 mg/day for ages 19–50, however only 50% of volunteers were achieving the recommended daily allowance (RDA) for
their age (1200 mg/day for ages 51+) [23]. Similar results are reported
for vitamin D intake. The average consumption for all participants met
the RDA, however 44% (n = 8) did not achieve the desirable intake
set by the Institute of Medicine.
When implementing the World Health Organization's deﬁnitions for
osteopenia and osteoporosis [24], bone scan results from baseline reveal
that 41% of participants (n = 7) and 24% (n = 4) were osteopenic or osteoporotic at the spine, respectively. At the hip, 56% (n = 10) were
osteopenic while another 17% (n = 3) met the criteria for diagnosis of
osteoporosis. No signiﬁcant changes in body weight occurred during
the exercise intervention (80.2 ± 20.0 vs. 81.2 ± 19.4, p = 0.32).
Paired t-tests comparing baseline values to those obtained after
26 weeks of training revealed signiﬁcant improvements in BMD at the
spine, hip, and whole body (Table 2). As a collective group, participants
experienced a 2.5% improvement in BMD at the spine, 1.7% at the hip,
and 2.0% of the whole body. Variables at baseline such as age, time
since treatment, physical activity, BMI, calcium and vitamin D intake
were not correlated to changes in BMD. When examining results by
treatment type, participants who underwent chemotherapy (n = 8),

Table 2
Changes in bone mineral density and body composition.
Measurement

Baseline

Follow-up

p-Valuea

Total spine BMD
Total hip
Whole body
Lean mass
Fat mass

0.971 ± 0.218
0.860 ± 0.184
1.002 ± 0.153
43.8 ± 8.7
35.2 ± 12.6

0.995 ± 0.218
0.875 ± 0.191
1.022 ± 0.159
44.7 ± 8.4
35.2 ± 12.6

0.012
0.048
0.002
0.044
0.990

Mean ± standard deviation.
BMD is bone mineral density in g/cm2 at the bone sites indicated.
Lean mass and fat mass of the whole body are in kg.
a
p-Value is displayed for a paired t-test conducted with SPSS version 22.
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experienced signiﬁcantly greater improvements in BMD at the spine
(0.2% vs. 4.9%, p b 0.05) and hip (0.2% vs. 3.6%, p b 0.05) in comparison
to participants who did not have chemotherapy treatment (n = 10)
but had radiation or surgery or both. Body composition derived from
the whole body DXA scan is also displayed in Table 2. Participants
showed signiﬁcant improvements in lean mass over the course of the
study adding nearly 1 kg of lean mass; however fat mass was maintained during the intervention leading to no signiﬁcant change in percent body fat.
Analysis of serum markers of bone turnover indicated a decrease in
bone metabolism during the exercise intervention (Fig. 1). P1NP was
22% lower at 13 weeks and 28% lower at 26 weeks in comparison to
baseline (p b 0.01). CTX showed a non-signiﬁcant decrease of 8% and
18%, 13 and 26 weeks after the start of the study, respectively. Further
analysis involving the removal of participants who were taking a medication known to alter bone metabolism did not change these ﬁndings.
4. Discussion
The goal of this investigation was to evaluate the effectiveness of
26 weeks of CART on BMD in female cancer survivors. We report significant improvements in BMD at the spine, hip, and whole body in this
convenience sample of females. Participants also experienced a signiﬁcant increase in lean mass while showing maintenance of fat mass. A
lack of adverse events and injuries during the IMPAACT program supports exercise as a safe way to improve health after cancer treatment.
Two investigations [25,26] report improvement in BMD at the hip
and spine in breast cancer survivors who performed strength training
exercise twice per week for 12 months, but their participants also
began bisphosphonate medication with calcium and vitamin D supplementation when initiating the exercise program. Additional beneﬁts
due to exercise without bisphosphonate medication use were not observed [25]. Other investigations involving walking [27], aerobic exercise [28], and resistance-training with a jumping protocol [29–31]
have demonstrated that exercise may help maintain bone health in cancer survivors.
Research shows that most women over the age of 40, lose an average
of 0.5% bone mass per year [15]. Several other researchers have reported
maintenance of bone mass with an exercise intervention in female cancer survivors of similar age to ours [25,29,30]. However, our
Bone Turnover Markers
0
0
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26

-5

% Change

-10
P1NP

-15

CTX

-20

-25

-30

Marker

Time (weeks)

Baseline

13 weeks

26 weeks

P1NP (ng/ml)

37.57 ± 4.77

29.43a ± 5.21

27.00a ± 2.08

CTX (ng/ml)

0.60 ± 0.43

0.55 ± 0.43

0.49 ± 0.40

mean ± standard deviation
a
p<0.01 significant change from baseline
Fig. 1. Bone turnover markers.
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participants, at the average age of 60 years (range: 40 to 80 years),
not only maintained bone mass but appear to have increased in bone
mineral density. Perhaps our participants experienced a measureable
increase in BMD because the weight-bearing exercises were precisely
selected for their potential to impact the skeleton. The 1.7–2.5% average
increase in BMD corresponds to improvements in T-scores at all bone
sites and may result in a clinically relevant reduction in future risk for
fracture [32]. In addition, incorporation of whole body vibration training
is novel and may have contributed to the osteogenic response. Percent
change in BMD should be interpreted with knowledge of the 1.0% coefﬁcient of variation in DXA bone measurements.
The IMPAACT program was developed to investigate the rehabilitative potential of supervised exercise on a comprehensive set of neural,
muscular, metabolic, as well as skeletal variables. Therefore, in order
to address the multiple comorbidities associated with cancer survivorship, we created an exercise intervention which involved aerobic and
resistance training, according to guidelines for exercise in cancer survivors set forth by the ACSM [21]. It is well accepted that weight-bearing
activity, including aerobic exercise and resistance training, can help preserve bone health in adults [15]. Previous research among female cancer
survivors has suggested that weight-bearing aerobic exercise [18] and
resistance training combined with impact exercise (jumping) helps to
preserve BMD [30,31]. It is likely that for healthy adults, walking alone
is not a sufﬁcient stimulus to contribute to improvements in bone
health, but may help improve cardiovascular ﬁtness and/or preserve
current bone mass [33]. Galvao et al. investigated combined aerobic
and resistance training in men undergoing androgen suppression therapy for prostate cancer [34]. In comparison to normal care, the CART intervention of Galvao et al. led to improved cardiovascular capacity, lean
mass, and strength despite the hypogonadal status involved with prostate cancer treatment (BMD was not a component of their investigation). Schwartz et al. found that aerobic weight-bearing exercise, such
as walking and jogging, preserved BMD better than resistance exercise
and usual care during active chemotherapy treatment in women
newly diagnosed with breast cancer [35]. Exercise selection and adherence involved with their home-based program and the current treatment status of their participants could explain the lack of skeletal
beneﬁt with the resistance exercise.
Subsequent analysis of BMD results in our participants by treatment
type revealed that those who underwent chemotherapy displayed signiﬁcantly greater improvements in bone mass during the exercise intervention than those who did not have chemotherapy. Deeper analysis of
bone health changes for those who underwent surgery or radiation revealed no additional meaningful information. Research by WintersStone et al. suggests that women with low initial values of BMD have
greater improvements in bone health due to exercise [13]. Further investigation conﬁrmed that this does not explain discrepant results by
treatment type in our participants, as baseline BMD values were similar
or slightly higher for those who had chemotherapy in comparison to
those who did not. Considering our small sample size, it is difﬁcult to
draw conclusions regarding this secondary ﬁnding; however it warrants
further investigation as to the skeletal beneﬁts of weight-bearing exercise by treatment type in cancer survivors.
The International Osteoporosis Foundation recommends serum
measurements of P1NP and CTX for interventional studies of bone
health [36]. P1NP and CTX values reported for participants in our
study were within the expected reference intervals reported in the literature [37]. However, few studies have reported BTMs in cancer survivors, a group at risk for poor bone health [7,38]. Greenspan et al.
reported similar decreases in P1NP and N-telopeptide cross-linked collage type I (NTX) in breast cancer survivors who underwent 12-months
of treatment with risendronate [39]. In another study of breast cancer
survivors, Toriola et al. reported signiﬁcant decreases in P1NP and
NTX markers, but no signiﬁcant change in CTX, for overweight and
obese women undergoing a weight loss intervention which included
exercise for some participants [40]. In contrast to our ﬁndings, their
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results showed a greater decrease at 12 months rather than 6 months,
as the rate of change in BTMs for our participants seemed to plateau
in the latter half of our intervention.
Eekman et al. report signiﬁcant reductions in P1NP and CTX for men
and women with osteoporosis who underwent three months of bisphosphonate treatment [41]. The 28% and 18% reduction in formation
and resorption markers in our population was not as large as those reported for Eekman et al. however we postulate that the changes in our
study are due to the exercise intervention, a conservative treatment approach to osteoporosis, rather than pharmacological therapy. Research
by Shah et al. complements our work in reporting a decrease in P1NP
and CTX for research participants who participated in a combined
aerobic and resistance training program for 1 year [42]. Similar to
our ﬁndings, the most drastic change in BTMs occurred in the ﬁrst
six months of the study which may have led to the measureable improvements in BMD at 12 months reported by Shah el al. and after
26 weeks of training as we report here. A decrease in bone resorption, although non-signiﬁcant in our ﬁndings, may have long-term
beneﬁts for bone health, especially in a mostly postmenopausal population such as ours where resorption can be high due to menopausal
status. Increase in BTMs can identify women at risk for fracture due
to bone loss, especially at clinically relevant sites such as the hip
and spine. Therefore a decrease in BTMs, as seen in our population,
is congruent with the improvements in BMD as changes in BTMs
are apparent well before changes in BMD.
A limitation of this investigation is the lack of a non-exercising comparison group. It is possible that all cancer survivors would experience a
rebound in bone mass after completion of treatment, however to our
knowledge, this has never been reported in the literature. Considering
that time since treatment was unrelated to change in bone mineral density and our participants had a mean of 6 years post-treatment, it is unlikely that the positive changes in bone health reported here were
simply due to recovery time rather than the intervention. It is possible,
that our participants would have displayed greater improvements in
bone mass due to an interaction effect of diet and exercise, if everyone
had been meeting the recommended daily allowance for calcium and
vitamin D, nutrients known to be important for bone health. Additionally, we measured dietary intake of vitamin D, which does not always reﬂect serum vitamin D status due to the ability to synthesize the
hormone from ultraviolet sun exposure. With our location in southern
California, it is possible that vitamin D status is adequate despite poor
dietary intake. Also, more than half of our participants performed their
aerobic activity for 20 min, three days/week, outside at noontime, possibly increasing their exposure to ultraviolet light. On the other hand,
mature adults synthesize vitamin D less efﬁciently and cancer survivors
could make a conscientious effort to avoid sun exposure in attempt to
reduce future risk of skin cancer [23]. Furthermore, previous research
suggests that physical activity can be osteogenic at calcium intakes ~
1000 mg/d [43]. While 50% of our participants were not meeting the
RDA for their age, 66% were achieving the 1000 mg/d threshold. Additional research suggests that weight-bearing exercise is more inﬂuential
on bone health than adequate calcium intake [44]. Future investigations
would improve upon this work by implementing a larger sample size,
limiting inclusion to one type of cancer, examining differential effects
of the mode of exercise, incorporating a non-exercising comparison
group, and assessing serum levels of vitamin D.

5. Conclusions
These results suggest that CART is safe and feasible for female cancer
survivors and could help improve bone health. With the increased number of women surviving cancer and experiencing cancer-induced bone
loss, survivorship care plans need to include exercise as a means to
maintain or improve bone health and reduce risk for osteoporosis in female cancer survivors.
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